Inventiva
Research Inventiva (IVA) on Bullrun: market cap USD 656.17M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIVA
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 656.17M
- Financial periodFY2025
- RevenueEUR 4.48M
- Revenue growth-51.3%
- Net income-EUR 354.14M
- Free cash flow-EUR 105.13M
- Gross margin150.3%
Valuation Snapshot
latest market cap is USD 656.17M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 4.48M | -EUR 354.14M | -EUR 105.13M | 150.3% | -1.9 | EUR 99.31M | EUR 59.86M | -EUR 28.52M |
| FY2024 | EUR 9.20M | -EUR 184.21M | -EUR 86.26M | 142.1% | -3.08 | EUR 96.56M | EUR 54.33M | -EUR 106.65M |
| FY2023 | EUR 17.48M | -EUR 110.43M | -EUR 82.15M | 124.7% | -2.43 | EUR 26.92M | EUR 37.49M | -EUR 32.03M |
| FY2022 | EUR 12.18M | -EUR 54.27M | -EUR 45.49M | 140.1% | -1.31 | EUR 86.74M | EUR 34.52M | EUR 45.48M |
| FY2021 | EUR 4.19M | -EUR 49.64M | -EUR 48.16M | 178.4% | -1.27 | EUR 86.55M | EUR 10.12M | EUR 88.87M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 656.17M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 898.27M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 204.72M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 233.44M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 187.92M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 558.33M | n/a | n/a | n/a |
About Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Inventiva's market cap?
Inventiva's market capitalization is USD 656.17M.
What does Inventiva do?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.